-
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline
•
On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan in B+ round financing. The round was led by CSCP Fund, with follow-on investments from institutions including Beta Fund. With this funding, BRL Medicine will accelerate the clinical translation and commercialization of its multi-pipeline products…
-
Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline
•
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm BRL Medicine Inc. The collaboration aims to deepen their involvement in the gene and cell therapy (GCT) pipeline, enhance clinical studies, and expedite the commercialization of novel therapies. BRL Medicine’s…
-
BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE
•
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval from China’s Center for Drug Evaluation (CDE) for its CD19-targeted chimeric antigen receptor (CAR)-T cell therapy, BRL-301. The therapy is set to be assessed as a treatment for acute lymphocytic leukemia (ALL). BRL-301: A Universal…
-
BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101
•
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major. The company reported the first cure in a multi-center Phase clinical study assessing the safety and efficacy of its BRL-101, an autologous hematopoietic stem progenitor cell therapy. This marks a major milestone in the development…
-
BRL Medicine Raises RMB 200M in Series B Financing for CGT Development
•
BRL Medicine Inc., a cell and gene therapy (CGT) developer based in Shanghai, has reportedly raised over RMB 200 million (USD 28.3 million) in a Series B financing round. The round was led by Shanghai FTZ Fund, with participation from Oriental Fortune Capital, Tasly Capital, Betta Biomedical Industry Fund, and…
-
BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia
•
Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the Center for Drug Evaluation (CDE) for its BRL-101. The therapy is an autologous hematopoietic stem progenitor cell treatment for transfusion-dependent beta-thalassemia. Drug DetailsBRL-101 is a gene therapy developed through BRL’s in-house developed hematopoietic stem cell…
